The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses

Virus Research

Volumn 147, Issue 2, 2010, Pages 176-181

  Brosnahan, Margaret M ^a   Damiani, Armando ^a,b   van de Walle, Gerlinde ^a,c   Erb, Hollis ^a   Perkins, Gillian A ^a   Osterrieder, Nikolaus ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Equine; Herpes myeloencephalopathy; Metaphylaxis; RNA interference

Indexed keywords

FIREFLY LUCIFERASE; GLYCOPROTEIN B; ORIGIN RECOGNITION COMPLEX; SMALL INTERFERING RNA; VIRUS DNA;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; EQUINE HERPES VIRUS; EXPERIMENTAL INFECTION; FEMALE; GENE TARGETING; HERPES VIRUS INFECTION; HORSE DISEASE; INFECTION PREVENTION; MALE; NEUROLOGIC DISEASE; NONHUMAN; NOSE SECRETION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA INTERFERENCE; VIRUS GENE;

ANIMALS; ANTIVIRAL AGENTS; BLOOD; BODILY SECRETIONS; DNA, VIRAL; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; LEUKOCYTES, MONONUCLEAR; MALE; NOSE; PREGNANCY; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TIME FACTORS;

EQUID HERPESVIRUS 1; EQUIDAE; HERPES;

EID: 72949114064     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.10.017     Document Type: Article

References (29)

1. Allen G.P. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. American Journal of Veterinary Research 69 12 (2008) 1595-1600
2. Allen G.P., Bolin D.C., Bryant U., Carter C.N., Giles R.C., Harrison L.R., Hong C.B., Jackson C.B., Poonacha K., Wharton R., and Williams N.M. Prevalence of latent neuropathogenic equine herpesvirus-1 in the Thoroughbred broodmare population of central Kentucky. Equine Veterinary Journal 40 2 (2008) 102-103
3. Allen G.P., and Breathnach C.C. Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1. Equine Veterinary Journal 38 3 (2006) 252-257
4. Bartlett D.W., and Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Research 34 1 (2006) 322-333
5. Bentz B.G., Maxwell L.K., Erkert R.S., Royer C.M., Davis M.S., MacAllister C.G., and Clarke C.R. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. Journal of Veterinary Internal Medicine 20 3 (2006) 589-594
6. Foote C.E., Love D.N., Gilkerson J.R., and Whalley J.M. Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm. Equine Veterinary Journal 36 4 (2004) 341-345
7. Fulton A., Peters S.T., Perkins G.A., Jarosinski K.W., Damiani A., Brosnahan M., Buckles E.L., Osterrieder N., and Van de Walle G.R. Effective treatment of respiratory alphaherpesvirus infection using RNA interference. PLoS ONE 4 1 (2009) 1-10
8. Furr M., and Reed S. Neurologic Examination, Equine Neurology (2008), Blackwell Publishing, Ames, IA pp. 65-76
9. Garre B., Gryspeerdt A., Croubells S., De Backer P., and Nauwynck H. Evaluation of orally administered valacyclovir in experimentally EHV-1 infected ponies. Veterinary Microbiology 135 (2009) 214-221
10. Garre B., van der Meulen K., Nugent J., Neyts J., Croubels S., De Backer P., and Nauwynck H. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, gancicyclovir, cidofovir, adefovir, PMEDAP and foscarnet. Veterinary Microbiology 122 (2007) 43-51
11. Gilkerson J.R., Love D.N., Drummer H.E., Studdert M.J., and Whalley J.M. Seroprevalence of equine herpesvirus 1 in Thoroughbred foals before and after weaning. Australian Veterinary Journal 76 10 (1998) 677-682
12. Goodman L.B., Loregian A., Perkins G.A., Nugent J., Buckles E.L., Mercorelli B., Kydd J.H., Palu G., Smith K.C., Osterrieder N., and Davis-Poynter N. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathogens 3 11 (2007) 1583-1592
13. Goodman L.B., Wagner B., Flaminio M., Sussman K.H., Metzger S.M., Holland R., and Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24 (2006) 3636-3645
14. Haasnoot J., Westerhout E.M., and Berkhout B. RNA interference against viruses: strike and counterstrike. Nature Biotechnology 25 12 (2007) 1435-1443
15. Harless W., and Pusterla N. Equine herpesvirus 1 and 4 respiratory disease in the horse. Clinical Techniques in Equine Practice 5 (2006) 197-202
16. Heinrich A., Riethmuller D., Gloger M., Schusser G.F., Giese M., and Ulbert S. RNA interference protects horse cells in vitro from infection with equine arteritis virus. Antiviral Research (2009)
17. Henninger R.W., Reed S.M., Saville W.J., Allen G.P., Hass G.F., Kohn C.W., and Sofaly C. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. Journal of Veterinary Internal Medicine 21 (2007) 157-165
18. Jarosinski K.W., Yunis R., O'Connell P.H., Markowski-Grimsrud C.J., and Schat K.A. Influence of genetic resistance of the chicken and virulence of Marek's disease virus (MDV) on nitric oxide responses after MDV infection. Avian Diseases 46 3 (2002) 636-649
19. Li B., Tang Q., Cheng D., Qin C., Xie F.Y., Wei Q., Xu J., Liu Y., Zheng B., Woodle M., Zhong N., and Lu P. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nature Medicine 11 9 (2005) 944-951
20. Maxwell L.K., Bentz B.G., Bourne D.W.A., and Erkert R.S. Pharmacokinetics of valacyclovir in the adult horse. Journal of Veterinary Pharmacology and Therapeutics 31 (2008) 312-320
21. Nugent J., Birch-Machin I., Smith K.C., Mumford J.A., Swann Z., Newton J.R., Bowden R.J., Allen G.P., and Davis-Poynter N. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. Journal of Virology 80 8 (2006) 4047-4060
22. O'Brien L. Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antiviral Research 75 (2007) 20-29
23. Patel J.R., Bateman H., William J., and Didlick S. Derivation and characterization of a live equid herpes virus-1 (EHV-1) vaccine to protect against abortion and respiratory disease due to EHV-1. Veterinary Microbiology 91 (2003) 23-39
24. Perkins G.A., Goodman L.B., Dubovi E.J., Kim S.G., and Osterrieder N. Detection of equine herpesvirus-1 in nasal swabs of horses by quantitative real time PCR. Journal of the American Veterinary Medical Association 22 (2008) 1234-1238
25. Slater J.D., Borchers K., Thackray A.M., and Field H.J. The trigeminal ganglion is a location for equine herpesvirus 1 latency and reactivation in the horse. Journal of General Virology 75 (1994) 2007-2016
26. Stassen L., Huismans H., and Theron J. Silencing of African horse sickness virus VP7 protein expression in cultured cells by RNA interference. Virus Genes 35 (2007) 777-783
27. Stevenson M. Therapeutic potential of RNA interference. The New England Journal of Medicine 351 (2004) 1772-1777
28. Van de Walle G.R., Goupil R., Wishon C., Damiani A., Perkins G.A., and Osterrieder N. A SNP in herpesvirus DNA polymerase is sufficient to cause lethal neurological disease. Journal of Infectious Disease 200 (2009) 20-25
29. van der Meulen K.M., Favoreel H.W., Pensaert M.B., and Nauwynck H.J. Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance. Veterinary Immunology and Immunopathology 111 (2006) 31-40